Compare LEN & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEN | KVUE |
|---|---|---|
| Founded | 1954 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Specialty Chemicals |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0B | 34.9B |
| IPO Year | N/A | 2023 |
| Metric | LEN | KVUE |
|---|---|---|
| Price | $89.86 | $17.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $103.46 | $19.73 |
| AVG Volume (30 Days) | 2.6M | ★ 25.1M |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | 2.13% | ★ 4.76% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | N/A | $4.80 |
| Revenue Next Year | $4.82 | $2.52 |
| P/E Ratio | ★ $15.20 | $22.96 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $92.17 | $14.02 |
| 52 Week High | $144.24 | $25.17 |
| Indicator | LEN | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 25.12 | 39.50 |
| Support Level | N/A | $17.14 |
| Resistance Level | $118.16 | $17.89 |
| Average True Range (ATR) | 2.96 | 0.30 |
| MACD | -0.93 | -0.11 |
| Stochastic Oscillator | 3.05 | 10.00 |
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.